restor3d, a leader in technology-driven personalized orthopedic solutions, announced a strategic investment partnership with Partners Group, one of the largest firms in the global private markets industry, acting on behalf of its clients. Under the agreement, Partners Group will acquire a significant minority stake in restor3d, marking the Company’s first institutional investment.
As part of this transaction, restor3d has raised a total of $104 million, including $65 million of new equity from Partners Group and $39 million from existing shareholders.
Founded in 2017, restor3d combines proprietary AI-driven design software, vertically integrated additive manufacturing, and rapid surgical planning to deliver implants tailored to both surgeon preference and patient anatomy. With FDA-cleared solutions across shoulder, hip, knee, foot, and ankle, restor3d empowers surgeons with high-quality, patient-specific implants that improve surgical fit and function. In 2024 alone, the Company partnered with more than 520 surgeons across 740 hospitals nationwide.
The proceeds from the investment will fuel continued product innovation, expand commercial growth, and broaden access to personalized orthopedic care. Partners Group will also join restor3d’s board of directors, contributing its deep operational experience and healthcare expertise to support the Company’s long-term strategy.
Also Read: Sunwest Credit Union and Tyfone Partner to Deploy Advanced Digital Transformation Strategy with nFinia Platform
“This investment marks an exciting milestone for restor3d as we expand access to personalized orthopedic solutions,” said Kurt Jacobus, CEO of restor3d. “With Partners Group’s support, we will continue to deliver innovations that empower surgeons and improve outcomes for patients across the full spectrum of joint replacement.”
Partners Group highlighted restor3d’s differentiated approach and strong market potential:
Ashley Torres, Member of Management, Private Equity, Partners Group, said: “restor3d is solving a key issue in the orthopedic market, namely that procedures have often relied on off-the-shelf products that cannot accommodate different patient anatomies. restor3d addresses this challenge by delivering rapid, precise patient-specific implants that lead to better surgical fit and function, ultimately improving patient outcomes.”
Todd Miller, Partner, Head Private Equity Health & Life, Partners Group, added: “We think restor3d’s offering is set to benefit from several thematic trends, including aging demographics and rising engagement in sports and recreational activities in the US. We look forward to working with the Company’s highly experienced management team.”
SOURCE: Businesswire